Electrocore LLC (ECOR)
electroCore, Inc. is a healthcare company focused on bioelectronic medicine and general wellness, with operations in the United States, the United Kingdom, and other international markets. The company’s non-invasive vagus nerve stimulation platform includes gammaCore, a prescription handheld device designed for acute treatment of migraine and episodic cluster headache pain, as well as for hemicrania continua and paroxysmal hemicrania. Its portfolio also includes Truvaga 350, a consumer wellness device, and Truvaga Plus, an app-enabled wellness product. electroCore additionally develops TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription device for primary headache conditions. Founded in 2005 and headquartered in Rockaway, New Jersey, the company’s common stock trades on NASDAQ under the symbol ECOR.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ECOR
|
$13.29
|
8.2% Upside
|
Fair
|
$19.17
|
56.0% Upside
|
Bargain
|
Good
|
0.0%
|
October 29, 2026
|
2.9x
|
110.8 M
|
107.7 M
|
8.1%
|
66.5%
|
-13.4
|
66.0%
|
